Universal Health Services (UHS)
(Delayed Data from NYSE)
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Zacks News
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Universal Health Services (UHS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
by Zacks Equity Research
Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
Stereotaxis (STXS) Receives European Approval for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised
by Zacks Equity Research
Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
by Zacks Equity Research
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain Ecolab (ECL) Stock in Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on cost efficiency programs raises optimism about the stock.
Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments
by Harshit Gupta
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.
Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare
by Zacks Equity Research
Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.
Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain
by Zacks Equity Research
Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
by Zacks Equity Research
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
5 Best of the Best Stock Picks: Strong Buys and VGM of A
by Tracey Ryniec
HRB, ANF, POWL, EME and UHS have value, growth, momentum, and rising earnings estimates.
J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery
by Zacks Equity Research
Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
by Zacks Equity Research
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Stryker's (SYK) Pangea System to Enhance Plating Solutions
by Zacks Equity Research
Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.
PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.
Vicarious Surgical (RBOT) Partners LSU Health New Orleans
by Zacks Equity Research
Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.